iktos

🌟 iktos is excited to participate in the upcoming Automated Synthesis Forum🇬🇧 Franck Le Vaillant, our Deputy Lab Head, will showcase how we are developing an autonomous drug discovery platform with a strong focus on our AI-driven approach to accelerate the synthesis of bioactive molecules. You won’t want to miss his talk! He will be joined by Nicolas Martin, PhD, our Director of European Business Development. They are both eager to connect with you at the forum to discuss how GenAI & Robotics can enhance your drug discovery process. 🤖💡 Looking forward to seeing you there! 👋 👉 https://lnkd.in/enUktD2a #robotics #artificialintelligence #PharmaTech #drugdiscovery #PharmaPartnership #Makya #Spaya #ASF2024

✨ Meet Friedrich Rippmann, PhD a visionary leader in AI-driven drug discovery ✨ We are thrilled to welcome him to our newly appointed Scientific Advisory Board! His pioneering work in integrating AI into drug discovery will be instrumental in advancing Iktos’s platform and accelerating pharmaceutical partnerships. 🌟 🔬 He is a seasoned drug discovery professional and former Director of Computational Chemistry and Biologics at Merck Group. As an early and visionary adopter of AI in pharma, he led transformative efforts to integrate AI and machine learning into drug discovery, revolutionizing how computational chemistry is applied across the pharmaceutical industry. His work on discovering and optimizing lead compounds and predicting molecular properties has had a lasting impact. 🚀 🎯 His extensive expertise in structure-based drug design and protein-ligand interactions has been critical in optimizing therapeutic candidates, while his current role as Director at CombinAble.AI reflects his ongoing commitment to innovation. There, he is driving the vision to make antibody candidates developable and manufacturable through novel proprietary computational methods. 🧬💡 💼 As a member of iktos’ Scientific Advisory Board, Friedrich Rippmann will bring his deep expertise in computational modeling and its integration into pharma, playing a pivotal role in enhancing our AI-first drug discovery partnerships. We are excited to have his guidance as we continue to transform drug discovery with AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

📖 Don’t miss the latest editorial in the Journal of Medicinal Chemistry from American Chemical Society. Weijun Xu explores how the growing synergy between Computer-Aided Drug Design (CADD) and Artificial Intelligence in Drug Discovery (AIDD), are unlocking complex therapeutic challenges and paving the way for next-gen medicines 💊. 💻 The article gives an up-to-date look at computational innovations—from deep learning to advanced molecular docking—and highlights key players like Insilico Medicine, Exscientia, Recursion, iktos, and more. 🌟 A perfect Friday read on the trends shaping the future of pharma, where AI-driven innovation is just getting started! ⚡️ 🔗 Read more: https://lnkd.in/ehtA3VeD #CADD #AIDD #ArtificialIntelligence #DrugDiscovery #PharmaTrends ACS Publications #JournalOfMedicinalChemistry

📖 Don’t miss the latest editorial in the Journal of Medicinal Chemistry from American Chemical Society. Weijun Xu explores how the growing synergy between Computer-Aided Drug Design (CADD) and Artificial Intelligence in Drug Discovery (AIDD), are unlocking complex therapeutic challenges and paving the way for next-gen medicines 💊. 💻 The article gives an up-to-date look at computational innovations—from deep learning to advanced molecular docking—and highlights key players like Insilico Medicine, Exscientia, Recursion, iktos, and more. 🌟 A perfect Friday read on the trends shaping the future of pharma, where AI-driven innovation is just getting started! ⚡️ 🔗 Read more: https://lnkd.in/ehtA3VeD #CADD #AIDD #ArtificialIntelligence #DrugDiscovery #PharmaTrends ACS Publications #JournalOfMedicinalChemistry

✨ Meet Dr. Laurent Debussche, first-in-human drug discovery expert✨ We are excited to welcome him to our new Scientific Advisory Board! His expertise will be invaluable in accelerating our AI-driven drug discovery pipeline to address unmet patient needs. 🌟 🔬 With over 35 years of experience in oncology R&D, Dr. Debussche has held senior leadership roles at major pharmaceutical companies. Most recently, he served as VP Global Head of Oncology Research at Sanofi, where he advanced several first-in-human oncology drug candidates. His work spans a wide range of technologies, including small molecules, monoclonal antibodies (MAbs), nanobodies, antibody-drug conjugates (ADCs), cell engagers, and more. 🚀 🎓 Currently, Dr. Debussche serves as CEO of DLog Consulting, where he provides expert guidance in oncology drug development and strategic R&D leadership. He has co-authored over 60 international scientific publications and holds several dozen patents. 🏅 With a PhD in Molecular Biology from Pierre and Marie Curie University, he has led innovative research initiatives throughout his career, addressing unmet medical needs. 💡 His deep expertise in advancing first-in-human targets to clinical development will be key to accelerating iktos’s AI-first drug discovery pipeline. We are delighted to have Dr. Debussche on board as we continue our mission to revolutionize drug discovery through AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

✨ Meet Prof. Rafael Gómez Bombarelli, a pioneer in AI-driven molecular design ✨ We are excited to welcome him to our new appointed Scientific Advisory Board! His expertise will significantly enhance the development of Iktos' technology and AI-first drug discovery pipeline. 🌟 🔬 As Paul M. Cook Career Development Professor at Massachusetts Institute of Technology, he works on the integration of AI and atomistic simulations for material and molecular design at the Learning Matter Lab. A pioneer in Generative AI for chemistry, his seminal work on molecular representations is now central to GenAI solutions in drug discovery, enabling faster and more cost-effective identification of promising compounds. 🚀 🎓 Dr. Gomez-Bombarelli holds a chemistry degree from the Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt University and Harvard University. His contributions have been widely recognized, earning him accolades such as the Sloan Fellowship, the The Camille and Henry Dreyfus Foundation “Machine Learning in the Chemical Sciences and Engineering Award”, and the Google Faculty Research Award. 🏅 💡 His entrepreneurial background is equally impressive: as a co-founder of Calculario, a Harvard spinout, and former Chief Learning Officer at ZebiAI, he has demonstrated the capacity to turn groundbreaking research into commercial ventures. 💼🔬 We are delighted to have Professor Gomez-Bombarelli with us as we continue our mission to revolutionize drug discovery through AI and Robotics. Follow us to meet other members of the board! 📢 Please learn more about our scientific board members: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

🗣️ "What really energizes me when attending BIO-Europe is the exchange of ideas— learning about unique approaches to solve some of the fundamental roadblocks in discovering novel medicines to address unmet needs. It’s even more exciting when we find that our platform can solve some of those very challenges." 👉 Meet Avirup Bose, Chief Business Officer at iktos at the BIO-Europe! With experience in 60+ targets and a an internal pipeline focused on oncology, inflammation and auto-immune diseases, Iktos is ready to partner with you. Let’s leverage our GenAI and robotics platform to accelerate your drug discovery. Connect with us at BIO-Europe 2024. https://lnkd.in/eNTdazp4 #BIOEurope #PharmaPartnership #ArtificialIntelligence #drugdiscovery

 (🇬🇧 message below) 〜学会に関するお知らせ〜 LinkedInコミュニティーの皆様こんにちは！ Iktos APACチームです 🙂 10月28日から東京、タワーホール船堀で行われるCBIに参加します。 10月29日午後2時からはスポンサードセッションを行います。弊社からは VictoireとHideyoshi Fuji が生成AIツールであるMakyaと共同研究の事例をご紹介します。また、Elsevier社からNaoko Suzuki様をスピーカーとしてお招きし、弊社のAI技術が搭載されたReaxys逆合成予測iktosについてご紹介いただきます。当日会場にお越しの方は是非ご参加ください！ 企業展示スペースにも3日間参加します。 新しいノベルティを用意してお待ちしておりますので、 こちらにも是非お越しください。 当日お会いできるのを心待ちにしています。 Our next conference in Japan is just around the corner! We invite you to join us at the Chem-Bio Informatics (CBI) Society 2024 Annual Meeting, taking place from October 28-31 in Tokyo, Japan. This event promises to drive innovation and foster new diversity through multifaceted modeling. Join our iktos representatives, Hideyoshi Fuji and Victoire M. L. Cachoux Cachoux, for a sponsor session on October 29th at 2 PM. They will explore Drug Discovery Innovation in the Age of Generative AI, alongside Naoko Suzuki from our partner, Elsevier. We look forward to connecting with you and discussing your drug discovery projects! Be sure to stop by our Iktos booth (#2). For more information, visit: https://lnkd.in/gzb8y5gd See you in Japan! 🇯🇵✨ #CBI #drugdiscovery #PharmaTech #InnovativeTherapies #artificialintelligence #Makya #Spaya #robotics 

🚀 Meet our new iktos Scientific Advisory Board! 🚀 We are honored to introduce 5 visionary leaders from Massachusetts Institute of Technology, and former executives from Eli Lilly and Company & Recursion, Merck Group, Sanofi, and ConjuChem, whose wealth of experience will be instrumental in enhancing our AI-first drug discovery platform, strengthening discovery collaborations, and advancing Iktos’ pipeline toward commercialization. 🌟 Rafael Gómez Bombarelli is an MIT professor and pioneer in Generative AI, whose seminal work on molecular representations is now central to AI-driven solutions in drug discovery, enabling faster and more cost-effective identification of promising compounds. 🤖 Thierry Masquelin is the visionary creator of the Lilly Life Science Studio (#L2S2) and former automation leader at Recursion Pharmaceuticals. He will guide us in advancing Iktos’ integrated synthesis, purification, and testing robotic platform, reducing drug discovery cycle times. 🔬 Friedrich Rippmann, former Director of Computational Chemistry and Biologics at Merck KGaA, is a trailblazer in applying AI to pharmaceutical research. His groundbreaking work on molecular property prediction revolutionized the use of computational chemistry in drug discovery. 🏥 Laurent Debussche, former VP of Oncology Research at Sanofi, brings decades of experience in progressing first-in-human drug candidates to clinical phases, addressing unmet medical needs. His expertise will be invaluable for us to drive an innovative pipeline of drug candidates. 💼 Dominique Bridon, Executive Chairman at Sybilla Therapeutics, will leverage his leadership reconciling excellence in science and innovation with entrepreneurial successes, including taking Conjuchem public. His experience in strategic pipeline management will help us mature and expand our pool of AI-first candidates. We are delighted to welcome our new Scientific Advisory Board and invite you to stay tuned for their insights on how Generative AI and Robotics are reshaping drug discovery! 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #InnovativeTherapies #ArtificialIntelligence

🔍 AI Drug Discovery: beyond the hype 🔍 Did you miss it? In a recent Genetic Engineering & Biotechnology News article, Exscientia, DeepCure, VeriSIM Life and Quentin Perron, iktos’ CSO, discuss AI’s game-changing impact on drug design, tackling some of the toughest challenges: ➡️ Engineering drugs with specific requirements from the outset—shifting drug discovery from a screening process into a learning one to deliver truly novel drugs. ➡️ Designing these novel drugs for automated synthesis—addressing the slowest bottlenecks to critically accelerate discovery timelines. ➡️ Eliminate unnecessary animal testing and predict a drug’s success before clinical trials. These breakthroughs are transforming the landscape of drug design and shaping the future of medicine - and our Drug Discovery platform is at the heart of it! 🧬✨ 👉 Read it here! https://lnkd.in/gKuQhEaz #DrugDiscovery #PharmaTech #InnovativeTherapies #ArtificialIntelligence